Navigation Links
Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call

SAN CARLOS, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it will hold a webcast and conference call to discuss results of the Phase 3 SONOMA-2 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase- 2) clinical trial presented at the upcoming American Society of Hematology (ASH) 49th Annual Meeting. The webcast will take place on Monday, December 10, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

To participate in the conference call, please dial 866-854-8095 for domestic callers and 706-634-8567 for international callers and reference conference passcode 26513597. A telephone replay of the conference call will be available through Monday, December 24, 2007. To access the replay, please dial 800-642-1687 for domestic callers and 706-645-9291 for international callers and reference conference passcode 26513597.

In addition, this call is being webcast by Thomson/CCBN and can be accessed via Nuvelo's website at The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (, a password-protected event management site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes alfimeprase, a direct acting fibrinolytic in Phase 2 clinical development for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion; and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a potential short- acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to continue its research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities. Information about Nuvelo is available at our website at or by phoning 650-517-8000.

SOURCE Nuvelo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
(Date:12/1/2015)... Sverige, December 1, 2015 ... Cancer Study Group (IBCSG, Bern ... ingå i en klinisk studie av palbociclib, ett ... --> Studien, med namn PYTHIA, kommer ... anti-hormonella läkemedel i kombination med palbociclib, som tillhör ...
(Date:11/30/2015)... , Dec. 1, 2015 Researchers have developed ... body part thickness and checks for motion, positioning and ... feasibility study presented today at the annual meeting of ... (RSNA). Steven Don , M.D., associate ... University School of Medicine in St. Louis, ...
(Date:11/30/2015)... Die MEDTEC Japan 2016, ... Entwicklung und Herstellung medizinischer Geräte, findet ... in Tokyo ... Foto: ... --> ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... December 01, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. ... the nation’s leading networking organization exclusively for professional women, boasting 850,000 members and ...
(Date:11/30/2015)... (PRWEB) , ... December 01, 2015 , ... ... Dale Jones as a 2015-2016 inductee into its VIP Woman of ... education. NAPW is the nation’s leading networking organization exclusively for professional women, boasting ...
(Date:11/30/2015)... , ... December 01, 2015 , ... ... latest carrier to offer individual vision insurance plans on . The ... ability to rate and review products, allowing consumers to compare, quote and match ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Until now, ... criteria set forth in the MOMS (Management of Myelomeningocele Study) trial. One of these ... Control and Prevention), a BMI of 18.5 to 24.9 is considered normal, 25 - ...
(Date:11/30/2015)... ... November 30, 2015 , ... Stress, anxiety, illness, infection or ... worry about possible tumors? , Heather Spader, MD, a new pediatric neurosurgeon at Joe ... some signs might point to tumors. , “Bad headaches that don’t go ...
Breaking Medicine News(10 mins):